WBC Disorders VIII Flashcards
chimeric BCR-ABL gene
chronic myeloid leukemia - CML
MPD
reciprocal (9;22) (q34;q11) translocation
philadelphia chromosome
90% creates the BCR-ABL gene of CML
BCR - 22
ABL - 9
myeloproliferative disorders
mostly - multipotent progenitor that gives rise to erythrocytes, platelets, granulocytes
less common - pleuripotent giving rise to lymphoid and myeloid clls
CML clinical
adult 50yo
males
fatigue, weak, weight loss, anorexia
abdominal pain/fullness - dragging sensation in abdomen
-due to EMH
LUQ pain - splenic infarct
sea blue histiocytes
scattered macrophage with wrinkled green-blue cytoplasm
in CML
diagnosis of CML
leukocytosis - possibly >100,000
hypercellular bone marrow - granulocytes, eosinos, basos, megas
-sea blue histiocytes and reticulin
LOW LAP**
detection of Ph1 or BCR-ABL fusion gene - chromosomal analysis or PCR based tests
LAP
leukocyte alkaline phosphatase
- low in CML
- high in reactive node - leukamoid rxn
CML prognosis
untreated - slow progression
3 year survival - no tx
50% accelerated phase - blast crisis in 6-12 months
-to AML (majority) or ALL
ikaros mutation
lymphoid blast crisis in CML
Tx of CML
BCR-ABL inhibitor - remission 90%
young pt - HSC transplant
panmyelosis
increased platelets
polycythemia vera
increased red cells, granulocytes, and platelets
RBC increase - polycythemia - most of symptoms
low EPO levels
low EPO, JAK 2 mutation, bone marrow study
polycythemia vera
P. rubra vera
polycythemia vera
PCV
polycythemia vera
clinical for polycythemia vera
late middle age
-insidious onset
pruritis, HA, HTN, GI ulcers, splenomegaly
elevated hematocrit**
bleeding and thrombosis
thrombocytosis >500,000 and many abnormal
DVT, MI, stroke
hyperuricemia - gout
Tx of polycythemia vera
phlebotomy - control RBC mass
-increase life expectancy from months to 10 years
JAK2 inhibitors
spent stage
polycythemia vera
aftet 10 years
fibrosis of marrow - and massive splenomegaly (due to EMH)
no tx with PCV
die from bleeding in months
essential thrombocytosis
increased platelet count
no polycythemia
point mutation in JAK2 or MPL
JAK2 or MPL mutation
essential thrombocytosis